55,209 Shares in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Bought by Corrado Advisors LLC

Corrado Advisors LLC acquired a new position in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 55,209 shares of the company’s stock, valued at approximately $638,000. Corrado Advisors LLC owned 0.67% of Global X Genomics & Biotechnology ETF as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. International Assets Investment Management LLC bought a new position in Global X Genomics & Biotechnology ETF during the fourth quarter worth about $100,000. Capital Analysts LLC lifted its holdings in Global X Genomics & Biotechnology ETF by 8.9% during the fourth quarter. Capital Analysts LLC now owns 18,732 shares of the company’s stock worth $217,000 after acquiring an additional 1,537 shares in the last quarter. Archford Capital Strategies LLC lifted its holdings in Global X Genomics & Biotechnology ETF by 15.6% during the fourth quarter. Archford Capital Strategies LLC now owns 23,076 shares of the company’s stock worth $267,000 after acquiring an additional 3,107 shares in the last quarter. Stratos Wealth Partners LTD. lifted its holdings in Global X Genomics & Biotechnology ETF by 9.3% during the third quarter. Stratos Wealth Partners LTD. now owns 39,001 shares of the company’s stock worth $397,000 after acquiring an additional 3,327 shares in the last quarter. Finally, Prosperity Wealth Management Inc. bought a new position in Global X Genomics & Biotechnology ETF during the fourth quarter worth about $544,000. 56.95% of the stock is owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Stock Performance

GNOM stock traded up $0.14 during midday trading on Tuesday, hitting $10.03. 64,549 shares of the company’s stock were exchanged, compared to its average volume of 68,765. The stock’s fifty day moving average price is $11.23 and its 200-day moving average price is $10.80. The company has a market cap of $91.43 million, a PE ratio of -4.28 and a beta of 1.30. Global X Genomics & Biotechnology ETF has a one year low of $8.63 and a one year high of $13.33.

Global X Genomics & Biotechnology ETF Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.